The FDA has approved a fluticasone propionate nasal spray USP metered at 0.05 mg per spray from Glenmark Pharmaceuticals for allergy symptoms, according to a press release from the company.
Glenmark said its spray is bioequivalent and therapeutically equivalent to Flonase (Haleon). Indications include nasal congestion, runny nose, sneezing, itchy nose and itchy and watery eyes in adults and children aged 4 years and older.
“This will increase access to an already proven treatment option by ensuring timely supply across the market,” Marc Kikuchi, MBA, president and business head, North America,